收稿日期: 2022-08-31
网络出版日期: 2022-12-19
基金资助
北京大学人民医院研究与发展基金(RDX2020-03)
Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome
Received date: 2022-08-31
Online published: 2022-12-19
Supported by
the Research and Development Fund of Peking University People's Hospital(RDX2020-03)
邢晓燕 , 张筠肖 , 朱冯赟智 , 王一帆 , 周新尧 , 李玉慧 . 皮肌炎合并巨噬细胞活化综合征5例[J]. 北京大学学报(医学版), 2022 , 54(6) : 1214 -1218 . DOI: 10.19723/j.issn.1671-167X.2022.06.026
To investigate the clinical and immunological features of dermatomyositis (DM) complicated with macrophage activation syndrome (MAS). The demographic and clinical characteristics of five patients diagnosed with DM complicated with MAS hospitalized in the Department of Rheumatology and Immunology, Peking University People ' s Hospital from 2011 to 2021 were collected. The results of clinical manifestations, laboratory tests, immunological features, treatments and prognosis were analyzed and summarized. In this study, five female patients in Peking University People's Hospital with an average age of 63.8 (44.0-83.0) years and an average disease duration of 16.1 (1.5-48.0) months. All the patients had typical DM rash (such as heliotrope sign, V/shawl sign or Gottron's sign/papules). They all had muscle involvement (including myalgia or muscle weakness). Two patients had positive myositis-specific antibodies (MSAs), in which case 1 had anti-TIF1-γ antibody and case 5 had anti-NXP-2 antibody. Four patients had interstitial lung disease except case 3. All of the cases developed MAS in the active stage of DM. Common manifestations of MAS in these five patients included high-grade fever, cytopenia, decreased fibrinogen, elevated ferritin and increased soluble CD25. Case 1 presented with neutropenia (0.6×109 /L), thrombocytopenia (26.0×109 /L), hypofibrinogenemia (0.9 g/L), markedly elevated ferritin (26 331.0 μg/L), decreased NK cell activity. Case 2 had anaemia (hemoglobin 81.0 g/L), thrombocytopenia (55.0×109 /L), hypertriglyceridemia (4.7 mmol/L), hypofibrinogenemia (1.2 g/L), elevated ferritin (>100 000.0 μg/L), hemophagocytosis in bone marrow. Case 3 had anaemia (hemoglobin 88 g/L), decreased fibrinogen (1.9 g/L), increased ferritin (>27 759.0 μg/L), splenomegaly, hemophagocytosis in bone marrow. Case 4 suffered from neutropenia(0.3×109 /L), anaemia(hemoglobin 78 g/L), hypertriglyceridemia (4.2 mmol/L), hypofibrinogenemia (0.9 g/L), increased ferritin (>100 000.0 μg/L), and decreased NK cell activity. Case 5 presented anaemia (hemoglobin 60.0 g/L), thrombocytopenia (67.0×109 /L), hypertriglyceridemia (12.7 mmol/L), decreased fibrinogen (1.1 g/L), and elevated ferritin (>923.0 μg/L). All the patients were treated with methylprednisone pulse therapy (200-500 mg) combined with cyclosporine while case 5 received rituximab after methylprednisone pulses. In addition, case 3 also received the combination of mycophenolate mofetil. Case 1 was given etoposide while case 4 was treated with cyclophosphamide and repeated plasmapheresis at the same time. Moreover, intravenous immunoglobulin was added meantime apart from case 3. The condition of four patients improved significantly, nevertheless case 4 experienced recurred pulmonary symptoms and died of respiratory failure. As for complications about infection, case 2 had bacterial infection with high level procalcitonin (PCT) before MAS treatment and condition was improved after empiric antibacterial therapy. Case 3 had cytomegalovirus DNAemia before diagnosis of MAS and viral titer turned negative after ganciclovir therapy. After treatment of MAS, four patients developed cytomegalovirus DNAemia except case 3, in which case 5 was co-infected with bacteria. To sum, DM complicated with MAS is relatively rare, and its patients are of ten in life-threatening condition. Early detection, treatment and prevention of infection during treatment are critical to improve the prognosis.
| 1 | Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347. |
| 2 | Lundberg IE , Tjarnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Ann Rheum Dis, 2017, 76 (12): 1955- 1964. |
| 3 | Henter JI , Horne A , Arico M , et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48 (2): 124- 131. |
| 4 | Lerkvaleekul B , Vilaiyuk S . Macrophage activation syndrome: Early diagnosis is key[J]. Open Access Rheumatol, 2018, 10, 117- 128. |
| 5 | Kumakura S , Murakawa Y . Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults[J]. Arthritis Rheumatol, 2014, 66 (8): 2297- 2307. |
| 6 | Liang J , Xu D , Sun C , et al. Hemophagocytic lymphohistiocytosis: Prevalence, risk factors, outcome, and outcome-related factors in adult idiopathic inflammatory myopathies[J]. J Rheumatol, 2020, 47 (10): 1532- 1540. |
| 7 | Minoia F , Davi S , Horne A , et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients[J]. Arthritis Rheumatol, 2014, 66 (11): 3160- 3169. |
| 8 | Tang S , Li S , Zheng S , et al. Understanding of cytokines and targeted therapy in macrophage activation syndrome[J]. Semin Arthritis Rheum, 2021, 51 (1): 198- 210. |
| 9 | Kostik MM , Dubko MF , Masalova VV , et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis[J]. Semin Arthritis Rheum, 2015, 44 (4): 417- 422. |
| 10 | Fardet L , Galicier L , Lambotte O , et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66 (9): 2613- 2620. |
| 11 | Schulert GS . The storm beneath the storm: MAS-HLH in inflammatory myopathies[J]. J Rheumatol, 2020, 47 (10): 1461- 1463. |
| 12 | Gono T , Kawaguchi Y , Ozeki E , et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis[J]. Mod Rheumatol, 2011, 21 (2): 223- 227. |
| 13 | La Rosee P , Horne A , Hines M , et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133 (23): 2465- 2477. |
| 14 | Canna SW , Girard C , Malle L , et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition[J]. J Allergy Clin Immunol, 2017, 139 (5): 1698- 1701. |
| 15 | Gabr JB , Liu E , Mian S , et al. Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: Case report and review of the literature[J]. Ann Transl Med, 2020, 8 (14): 887. |
| 16 | Ahmed A , Merrill SA , Alsawah F , et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: An open-label, single-centre, pilot trial[J]. Lancet Haematol, 2019, 6 (12): e630- e637. |
| 17 | Verweyen E , Holzinger D , Weinhage T , et al. Synergistic signaling of TLR and IFNalpha/beta facilitates escape of IL-18 expression from endotoxin tolerance[J]. Am J Respir Crit Care Med, 2020, 201 (5): 526- 539. |
| 18 | Wu J, Sun L, Tang X, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis associated refractory macrophage activation syndrome[J]. Mod Rheumatol, 2021[2022-08-01]. https://doi.org/10.1093/mr/roab119. |
| 19 | Fujita Y , Fukui S , Suzuki T , et al. Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis[J]. Intern Med, 2018, 57 (23): 3473- 3478. |
| 20 | Kaieda S , Yoshida N , Yamashita F , et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis[J]. Mod Rheumatol, 2015, 25 (6): 962- 966. |
| 21 | Komiya Y , Saito T , Mizoguchi F , et al. Hemophagocytic syndrome complicated with dermatomyositis controlled successfully with infliximab and conventional therapies[J]. Intern Med, 2017, 56 (23): 3237- 3241. |
| 22 | Sasaki H , Kohsaka H . Current diagnosis and treatment of polymyositis and dermatomyositis[J]. Mod Rheumatol, 2018, 28 (6): 913- 921. |
| 23 | Gavand PE , Serio I , Arnaud L , et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients[J]. Autoimmun Rev, 2017, 16 (7): 743- 749. |
/
| 〈 |
|
〉 |